Does PCOS Affect Embryo Quality? What PGT-A Studies Show

Is “Are My Eggs Bad?” Actually Three Different Questions?

Yes, and collapsing them into one is the single biggest source of confusion in how this topic gets discussed. A PCOS retrieval typically yields more oocytes than an age-matched non-PCOS cycle — that is a quantity finding. A smaller share of those extra oocytes are mature enough to fertilize — that is a maturity finding. And whether a resulting embryo carries the correct number of chromosomes is a third, separate finding, measured by an entirely different test (preimplantation genetic testing for aneuploidy, or PGT-A) on the embryo itself, days after fertilization. A study can find a difference on one of these and no difference on another, and most of the confusion around “does PCOS affect egg quality” comes from a source blurring the three together.

The quantity and maturity findings are covered in full, with the actual retrieval-stage numbers, on this site’s dedicated page on what a PCOS egg retrieval count predicts — a large meta-analysis found PCOS cycles retrieve 3.67 more oocytes on average than non-PCOS cycles, but only 2.16 of those extra oocytes are mature (Tang et al., 2021). This page does not re-derive that funnel. What it covers is the third question specifically: once an oocyte is mature and fertilizes, does the resulting embryo carry the right number of chromosomes at the same rate as a non-PCOS embryo — and the honest answer from the PGT-A literature is more specific, and more interesting, than a flat “no difference.”

What Did the Largest PGT-A Comparison Find?

No significant difference in aneuploidy, in the largest single comparison available. A secondary analysis of a multicenter randomized controlled trial identified 190 women with PCOS and 190 1:1 age-matched non-PCOS patients from 14 reproductive centers, all of whom had undergone PGT-A — 380 patients and 1,118 embryos in total. After adjusting for confounders, the embryonic aneuploidy rate was 14.0% in the PCOS group versus 18.3% in the control group (adjusted odds ratio 0.78, 95% CI 0.54–1.12, P = .19) — numerically lower in PCOS, but not a statistically significant difference. The embryonic mosaic rate was likewise similar: 10.9% versus 10.1% (adjusted OR 0.91, 95% CI 0.59–1.40, P = .66). Stratifying by all four PCOS phenotypes found no significant difference between any single phenotype and the control group either (Wang et al., 2023).

That is a real, specific, adequately powered finding — not “studies show.” It is also not the final word, because a larger multi-center study measuring the same thing found something more textured.

Did Every Study Find “No Difference”? What Does the Larger Study Show?

No — and the honest picture is more specific than “no difference,” in a way that matters. A multi-center retrospective cohort spanning cycles from 2015 to 2021 compared 707 blastocysts from 147 women with PCOS against 3,006 blastocysts from 821 control women, all undergoing PGT. It found PCOS blastocysts had a significantly lower aneuploidy rate — 15.2% versus 25.2% per woman, and 14.7% versus 25.4% per blastocyst (both P < .001) — but a significantly higher mosaicism rate: 12.5% versus 8.0% per woman, and 16.5% versus 8.7% per blastocyst (P = .007 and P < .001). A mixed model identified PCOS as an independent protective factor against aneuploidy (adjusted odds ratio 0.68, 95% CI 0.50–0.93) but an independent risk factor for mosaicism (adjusted odds ratio 1.52, 95% CI 1.11–2.10) — and the same model flagged insulin resistance specifically as a likely driver of the excess mosaicism (adjusted odds ratio 2.17, 95% CI 1.10–4.31) (Luo et al., 2024).

Neither of the first two rows is wrong, and they are not a contradiction to explain away. One is a null result in a well-designed, adequately sized study. The other is a specific, statistically significant, mechanistically explained finding — a plausible insulin-resistance pathway, not a population-wide “worse eggs” story — in a still larger one. A matched case-control study of one specific, milder PCOS phenotype (ovulatory, no excess androgen) found blastocyst euploidy rates comparable between groups once age, BMI, oocyte number, and sperm quality were matched (Vaiarelli et al., 2024) — a third data point, in a third population, pointing the same general direction as the larger studies. Taken together, the weight of the PGT-A evidence does not support “PCOS embryos are more often chromosomally abnormal.” It does support a more specific finding: PCOS may shift some chromosomally abnormal embryos from the aneuploid category into the mosaic category rather than eliminating the abnormality altogether — a distinction with real clinical stakes, since mosaic embryos are managed differently in a transfer decision than either euploid or fully aneuploid ones.

Is This the Same Finding as “PCOS Doesn’t Affect Egg Quality”?

Not exactly, and the distinction matters. A separate line of evidence looks at the oocyte itself, before fertilization — maturation rate and morphological grading under the microscope — rather than at the embryo’s chromosomes days later. A prospective study of 1,013 oocytes from 97 women with polycystic ovarian morphology against 774 oocytes from 97 matched controls found equivalent rates of mature (metaphase II) oocytes and equivalent rates of morphologically abnormal oocytes between the two groups, with the polycystic-ovary group going on to higher implantation and clinical pregnancy rates (Sigala et al., 2015). That is a real finding, and it answers a real question — but it is an oocyte-stage, pre-fertilization measurement, not a chromosomal one. This site’s dedicated page on PCOS and egg quality covers that fuller oocyte-quality picture, including what a high AMH does and does not predict, and this article does not repeat it. What this page adds is the layer that sits after fertilization: whether the resulting embryo’s chromosomes come out normal, which is a different biological checkpoint than oocyte maturity or morphology, tested by a different method, on a different day.

Does Age Still Matter the Same Way It Does for Everyone Else?

Yes, and nothing in the PCOS-specific PGT-A literature above changes that. Oocyte and embryo aneuploidy rises with maternal age regardless of PCOS status — that is one of the most consistently replicated findings in reproductive medicine, and none of the three studies above claim otherwise. A 25-year-old and a 42-year-old with the same PCOS diagnosis are not starting from the same age-related chromosomal risk, and a comparison showing PCOS is not worse than an age-matched control says nothing about whether either group’s numbers look different at a different age. The studies above matched PCOS and control groups by age specifically so that PCOS itself, not age, could be isolated as the variable — which means their findings describe “PCOS versus non-PCOS at the same age,” not “PCOS makes age irrelevant.”

Who This Does Not Reassure

The evidence above answers a narrower question than “will my embryos be fine,” and saying so plainly is the more useful answer than a blanket reassurance would be.

• This is not a promise about any individual result. A population-level finding of “no significant difference” describes the average across a study group, not what a specific retrieval will produce. Age, phenotype, ovarian response, and lab conditions all move an individual result independently of any of the percentages above.
• Mosaicism is real, even where aneuploidy is not. The largest study here found PCOS blastocysts had a mosaic rate roughly 50% to 90% higher than controls, with insulin resistance implicated as a possible mechanism. That is a genuine, if narrower, chromosomal difference — not nothing.
• A euploid result does not remove every other PCOS-related pregnancy risk. Chromosomal status is one variable among several that affect whether a pregnancy continues; this site’s PCOS miscarriage rate data covers that separately, on its own evidence base, and it is not resolved by a normal PGT-A result alone.
• None of the three studies above sorted results by every PCOS phenotype in fine detail. Wang et al. checked all four phenotypes and found no significant difference in any of them individually, but the insulin-resistance signal in the Luo et al. mosaicism finding suggests phenotype-level detail is where the next real question sits, not a settled non-issue.
• This is not a substitute for what your own retrieval and fertilization numbers say. How many eggs were retrieved and how many were mature is a separate, earlier question, covered by this site’s PCOS egg retrieval numbers, and a quoted clinic success rate depends heavily on which denominator it uses.

You may see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organizations renamed it. Every figure on this page applies under either name — this article uses PCOS because that is still what most readers search.

For the broader picture of PCOS and fertility treatment beyond this one question, PCOSguides’ fertility section covers ovulation induction, IVF, and the decision points around each.